This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, your body may not process ergotamine or ergotamine derivatives properly.
What might happen:
Your blood levels of ergotamine or ergotamine derivative may increase and cause toxic effects.
What you should do about this interaction:
Contact your healthcare professional (e.g. doctor or pharmacist) right away about using these medicines together. Your doctor may not want you to take your ergotamine derivative while you are taking your antibiotic.If you experience chest pain; change in heartbeat; numbness and tingling of hands, feet, or face; pain in arms, legs, or lower back; itching; or other symptoms while taking both of these medicines, contact your doctor.Your healthcare professionals (e.g. doctor or pharmacist) may already be aware of this drug interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Lu WJ, Huang K, Lai ML, Huang JD. Erythromycin alters the pharmacokinetics of bromocriptine by inhibition of organic anion transporting polypeptide C-mediated uptake. Clin Pharmacol Ther 2006 Oct;80(4):421-2.
2.D. H. E. 45 (dihydroergotamine mesylate) US prescribing information. Xcel Pharmaceuticals September, 2002.
3.Cafergot (ergotamine tartrate and caffeine) Suppositories US prescribing information. Novartis Pharmaceuticals Corporation June, 2002.
4.Methergine (methylergonovine maleate) US prescribing information. Novartis Pharmaceuticals Corporation June, 2012.
5.Biaxin (clarithromycin) US prescribing information. AbbVie, Inc. January, 2015.
6.Francis H, Tyndall A, Webb J. Severe vascular spasm due to erythromycin-ergotamine interaction. Clin Rheumatol 1984 Jun;3(2):243-6.
7.Collet AM, Moncharmont D, San Marco JL, Eissinger F, Pinot JJ, Laselve L. Iatrogenic ergotism. Responsibility of an ergotamine tartrate- erythromycine propionate association (author's transl). Sem Hop 1982 Jul 1;58(26-27):1624-6.
8.Ghali R, De Lean J, Douville Y, Noel HP, Labbe R. Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy. Ann Vasc Surg 1993 May;7(3):291-6.
9.Chignier E, Riou R, Descotes J, Meunier P, Courpron P, Vignon G. Acute iatrogenic ergotism by drug association. Diagnosis through non- invasive exploration (Doppler velocimetry (author's transl). Nouv Presse Med 1978 Aug 26-Sep 2;7(28):2478.
10.Matthews NT, Havill JH. Ergotism with therapeutic doses of ergotamine tartrate. N Z Med J 1979 Jun 27;89(638):476-7.
11.Hayton AC. Precipitation of acute ergotism by triacetyloleandomycin. N Z Med J 1969 Jan;69(440):42.
12.Bigorie B, Aimez P, Soria RJ, Samama F, di Maria G, Guy-Grand B, Bour H. Is triacetyl oleandomycin-ergotamine tartrate combination dangerous?. Nouv Presse Med 1975 Nov 8;4(38):2723-5.
13.Monsarrat M, Lefebvre D, Parraguette J, Vaysse C, Bastide G. Acute ergotism caused by an ergotamine-oleandomycin combination. Nouv Presse Med 1982 Feb 20;11(8):603.
14.Horowitz RS, Dart RC, Gomez HF. Clinical ergotism with lingual ischemia induced by clarithromycin- ergotamine interaction. Arch Intern Med 1996 Feb 26;156(4):456-8.
15.Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C. Dihydroergotamine-erythromycin-induced ergotism. Ann Intern Med 1988 Aug 1;109(3):249.
16.Franco A, Bourlard P, Massot C, Lecoeur J, Guidicelli H, Bessard G. Acute ergotism caused by dihydroergotamine-triacetyloleandomycin association. Nouv Presse Med 1978 Jan 21;7(3):205.
17.Vayssairat M, Fiessinger JN, Bequemin MH, Housset E. Dihydroergotamine and triacetyloleandomycin combination. Its role in iatrogenic necrosis of the fingers. Nouv Presse Med 1978 Jun 10;7(23):2077.
18.Boucharlat J, Franco A, Carpentier P, Charignon Y, Denis B, Hommel M. Ergotism in a psychiatric setting caused by combined dihydroergotamine- erythromycin propionate. Apropos of a case. Ann Med Psychol (Paris) 1980 Mar;138(3):292-6.
19.Neveux E, Lesgourgues B, Luton JP, Guilhaume B, Bertagna, Picard J. Acute ergotism caused by the interaction of erythromycin propionate and dihydroergotamine. Nouv Presse Med 1981 Sep 26;10(34):2830.
20.Couet W, Mathieu HP, Fourtillan JB. Effect of ponsinomycin on the pharmacokinetics of dihydroergotamine administered orally. Fundam Clin Pharmacol 1991;5(1):47-52.
21.Nelson MV, Berchou RC, Kareti D, LeWitt PA. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin Pharmacol Ther 1990 Jun;47(6):694-7.
22.Delaforge M, Riviere R, Sartori E, Doignon JL, Grognet JM. Metabolism of dihydroergotamine by a cytochrome P-450 similar to that involved in the metabolism of macrolide antibiotics. Xenobiotica 1989 Nov;19(11):1285-95.
23.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.